获得性BRAF V600E突变作为第三代EGFR酪氨酸激酶抑制剂治疗后的耐药机制。 - Suppr

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor.

作者信息

Bearz Alessandra, De Carlo Elisa, Doliana Roberto, Schiappacassi Monica

机构信息

Department of Clinical Oncology, Centro di riferimento oncologico Aviano National Cancer Institute, Aviano, Pordenone, Italy.

出版信息

J Thorac Oncol. 2017 Nov;12(11):e181-e182. doi: 10.1016/j.jtho.2017.07.017.

DOI:10.1016/j.jtho.2017.07.017

PMID:29074209

Abstract

摘要

相似文献

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor.获得性BRAF V600E突变作为第三代EGFR酪氨酸激酶抑制剂治疗后的耐药机制。

J Thorac Oncol. 2017 Nov;12(11):e181-e182. doi: 10.1016/j.jtho.2017.07.017.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib.奥希替尼治疗后获得 BRAF V600E 突变作为耐药机制。

J Thorac Oncol. 2017 Mar;12(3):567-572. doi: 10.1016/j.jtho.2016.11.2231. Epub 2016 Dec 5.

Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.使用连续液体活检来挑战 NSCLC 中的 BRAF/EGFR 共抑制。

Lung Cancer. 2019 Jul;133:45-47. doi: 10.1016/j.lungcan.2019.05.003. Epub 2019 May 4.

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.EGFR 突变型非小细胞肺癌患者中，同时获得性 BRAF V600E 突变和 MET 扩增作为一线奥希替尼治疗耐药机制

J Thorac Oncol. 2018 Jun;13(6):e89-e91. doi: 10.1016/j.jtho.2018.03.013. Epub 2018 Mar 27.

Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF mutation.一名携带获得性BRAF突变的EGFR突变型非小细胞肺癌患者对达拉非尼、曲美替尼和奥希替尼联合治疗的反应。

Lung Cancer. 2020 Jan;139:219-220. doi: 10.1016/j.lungcan.2019.10.014. Epub 2019 Oct 14.

Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.在不同病变部位存在异质性的患者中，同时使用奥希替尼和维莫非尼联合靶向 EGFR 和 BRAF 可触发奥希替尼耐药的消退。

Thorac Cancer. 2022 Feb;13(3):514-516. doi: 10.1111/1759-7714.14295. Epub 2021 Dec 27.

Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.奥希替尼联合达拉非尼和曲美替尼治疗奥希替尼诱导的BRAF V600E突变的晚期非小细胞肺癌患者。

Lung Cancer. 2020 Aug;146:358-361. doi: 10.1016/j.lungcan.2020.05.036. Epub 2020 Jun 4.

Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.在携带 EGFR 外显子 19 缺失的 NSCLC 细胞系中，获得 BRAF G469A 突变作为对一线奥希替尼治疗的耐药机制。

Target Oncol. 2019 Oct;14(5):619-626. doi: 10.1007/s11523-019-00669-x.

Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.携带EGFR突变和BRAF V600E的肺腺癌对奥希替尼和维莫非尼联合用药有反应，可克服奥希替尼耐药性。

Clin Lung Cancer. 2021 May;22(3):e390-e394. doi: 10.1016/j.cllc.2020.06.008. Epub 2020 Jun 11.

Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.获得性BRAF V600E突变介导对奥希替尼耐药并对奥希替尼、达拉非尼和曲美替尼联合治疗有反应。

J Thorac Oncol. 2019 Oct;14(10):e236-e237. doi: 10.1016/j.jtho.2019.05.040.

引用本文的文献

Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study.中国BRAF-V600突变晚期非小细胞肺癌的患病率、基因变异及临床结局：一项回顾性真实世界多中心研究

EBioMedicine. 2025 Apr;114:105652. doi: 10.1016/j.ebiom.2025.105652. Epub 2025 Mar 25.

Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover.胡椒碱通过调控泛素化介导的Sp1周转克服奥希替尼耐药性。

JCI Insight. 2025 Mar 24;10(6):e186165. doi: 10.1172/jci.insight.186165.

A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC.一项真实世界研究分析了驱动基因阳性 NSCLC 靶向治疗耐药后的继发 BRAF 变异。

Sci Rep. 2024 Sep 1;14(1):20302. doi: 10.1038/s41598-024-71143-6.

Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略

Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。

J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.

Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.非小细胞肺癌中获得性耐药对第三代表皮生长因子受体抑制剂的临床前模型：功能研究及用于克服耐药的联合用药

Front Oncol. 2022 Apr 7;12:853501. doi: 10.3389/fonc.2022.853501. eCollection 2022.

Thorac Cancer. 2022 Feb;13(3):514-516. doi: 10.1111/1759-7714.14295. Epub 2021 Dec 27.

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.拉米轮素 14 是一种海洋生物碱衍生物，可抑制 T790M/C797S 突变型表皮生长因子受体。

Cancer Sci. 2021 May;112(5):1963-1974. doi: 10.1111/cas.14839. Epub 2021 Mar 24.

Construction and Validation of a Protein Prognostic Model for Lung Squamous Cell Carcinoma.构建和验证肺鳞状细胞癌的蛋白质预后模型。

Int J Med Sci. 2020 Sep 23;17(17):2718-2727. doi: 10.7150/ijms.47224. eCollection 2020.

MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.MET 扩增导致接受厄洛替尼治疗的 EGFR 突变型肺癌对奥希替尼的异质性反应。

Cancer Sci. 2020 Oct;111(10):3813-3823. doi: 10.1111/cas.14593. Epub 2020 Sep 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third-Generation EGFR Tyrosine Kinase Inhibitor.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献